Global Anti-Aging Longevity Market By Clinical Phases (Research & Pre-Clinical, Phase I, Phase II, Phase III); By Therapy (Senolytic Drug Therapy, Gene Therapy, Immunotherapy, Stem Cell Therapy, Others); By Indication (Neurogenerative Diseases, Oncology, Tissue Homeostasis and Repair, Cardio-vascular diseases, Others); By End User (Hospital and Clinics, Academic and Research Institutions, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Global anti-aging longevity market is expected to reach US$ 119.62 Bn by 2030, growing at an estimated CAGR of 6.8% over the forecast period (2022 – 2030). Each passing day, the medical science is making rampant progress and treatment of most of the diseases is very much possible. The treatment of certain diseases which seemed impossible couple of years back can now be done with the help of latest technology and advanced drugs and therapies. Rise of pharmaceutical companies hugely contributes to the growth of the healthcare sector which currently values over trillion dollars. One such market that is part of healthcare sector and is witnessing huge growth is the anti-aging longevity market. It is rampantly growing owing to rise in the number of aging populations along diseases linked to it. Sedentary lifestyle and consumption of junk food is helping this market grow significantly.
The dynamics of the anti-aging longevity market changed after arrival of COVID-19 pandemic. People tried to find alternatives to conventional medicines and therapies in order to keep the dreadful infection at bay. This market saw massive growth at the time when other industries incurred huge losses.
Clinical Phases Outlook
On the basis of clinical phases, the anti-aging longevity market has been divided into research & pre-clinical, phase I, phase II, and phase III. The research & pre-clinical segment account for maximum amount of revenue generated by this market. In order to get complete approvals and authorization, any drug or treatment has to be full-proof in terms of efficacy and no side effects. Only after the drug ticks all boxes, it is granted authorisation and rolled out in the market.
Global Anti-Aging Longevity Market Revenue & Forecast, (US$ Million), 2022 – 2030
Therapy Outlook
On the basis of therapy, the anti-aging longevity market has been segmented into senolytic drug therapy, gene therapy, immunotherapy, stem cell therapy and others. The gene therapy segment dominates in terms of market share. Treatment of most of the diseases can be done effectively when the drug or therapy involves gene as it attacks root cause of any ailment. Gene therapy is showing great results in the treatment of diseases like cancer, which kill more people each year.
Indication Outlook
The indication segment of the anti-aging longevity market has been categorised into neurogenerative diseases, ophthalmic conditions, metabolic diseases, oncology, tissue homeostasis and repair, cardio-vascular diseases and others. The oncology segment generates most of the money for this market. This is primarily because number of people suffering from dreadful cancer are on a rise. Tumours are more prevalent in today’s time and hence anti-aging longevity therapy proves extremely helpful.
End User Outlook
The end user segment of the anti-aging longevity market has been bifurcated into hospital and clinics, academic and research institutions, and others. The hospitals and clinics account for maximum of revenue for this market. These two places are the most sought after in usual scenario when tries to seek any type of treatment. Hospitals and clinics are effectively using anti-aging longevity therapies.
Region Outlook
On the basis of region, the anti-aging longevity market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of the North America has been making most amount of money for this market. This is majorly because of the developed healthcare sector in countries like the United States and Canada. Advanced medical sector and availability of high-quality drugs makes North America an ideal market place for the anti-aging longevity market.
Competitive Landscape
The report provides both, qualitative and quantitative research of anti-aging longevity market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global anti-aging longevity market are listed below:
- AgeX Therapeutics, Inc.
- Bristol-Myers Squibb Company
- Calico Life Sciences LLC
- Life Biosciences, Inc.
- Merck & Co., Inc.
- Oisin Biotechnologies
- Pfizer Inc.
- A. Sciences, Inc.
- Unity Biotechnology
- Other Market Participants
Global Anti-Aging Longevity Market
By Clinical Phases
- Research & Pre-Clinical
- Phase I
- Phase II
- Phase III
By Therapy
- Senolytic Drug Therapy
- Gene Therapy
- Immunotherapy
- Stem Cell Therapy
- Others
By Indication
- Neurogenerative Diseases
- Ophthalmic Conditions
- Metabolic Diseases
- Oncology
- Tissue Homeostasis and Repair
- Cardio-vascular diseases
- Others
By End User
- Hospital and Clinics
- Academics and Research Institutions
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1.
Historic Years: 2015 –
2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market
Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Anti-Aging Longevity Market
6. Market Synopsis:Â
Anti-Aging Longevity Market
7. Anti-Aging LongevityÂ
Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in
Anti-Aging Longevity Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Anti-Aging Longevity Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Anti-Aging Longevity Market
8. Global Anti-Aging LongevityÂ
Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Anti-Aging LongevityÂ
Market Revenue (US$ Mn)
8.2. Global
Anti-Aging Longevity Market Revenue (US$
Mn) and Forecasts, By Clinical Phases
8.2.1. Research and Pre-Clinical
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2021
8.2.1.3. Market Forecast, 2022 – 2030
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2021
8.2.1.5.1.2. Market
Forecast, 2022 – 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2021
8.2.1.5.2.2. Market
Forecast, 2022 – 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2021
8.2.1.5.3.2. Market
Forecast, 2022 – 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2021
8.2.1.5.4.2. Market
Forecast, 2022 – 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2021
8.2.1.5.5.2. Market
Forecast, 2022 – 2030
8.2.2. Phase I
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2021
8.2.2.3. Market Forecast, 2022 – 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2021
8.2.2.5.1.2. Market
Forecast, 2022 – 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2021
8.2.2.5.2.2. Market
Forecast, 2022 – 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2021
8.2.2.5.3.2. Market
Forecast, 2022 – 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2021
8.2.2.5.4.2. Market
Forecast, 2022 – 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2021
8.2.2.5.5.2. Market
Forecast, 2022 – 2030
8.2.3. Phase II
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2021
8.2.3.3. Market Forecast, 2022 – 2030
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2021
8.2.3.5.1.2. Market
Forecast, 2022 – 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2021
8.2.3.5.2.2. Market
Forecast, 2022 – 2030
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2021
8.2.3.5.3.2. Market
Forecast, 2022 – 2030
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2021
8.2.3.5.4.2. Market
Forecast, 2022 – 2030
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2021
8.2.3.5.5.2. Market
Forecast, 2022 – 2030
8.2.4. Phase III
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2021
8.2.4.3. Market Forecast, 2022 – 2030
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market
Estimation, 2015 - 2021
8.2.4.5.1.2. Market
Forecast, 2022 – 2030
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 - 2021
8.2.4.5.2.2. Market
Forecast, 2022 – 2030
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market
Estimation, 2015 - 2021
8.2.4.5.3.2. Market
Forecast, 2022 – 2030
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 - 2021
8.2.4.5.4.2. Market
Forecast, 2022 – 2030
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market
Estimation, 2015 - 2021
8.2.4.5.5.2. Market
Forecast, 2022 – 2030
8.3. Key
Segment for Channeling Investments
8.3.1. By Clinical Phases
9. Global Anti-Aging LongevityÂ
Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global
Anti-Aging Longevity Market Revenue (US$
Mn) and Forecasts, By Therapy
9.2.1. Senolytic Drug Therapy
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2021
9.2.1.3. Market Forecast, 2022 – 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2021
9.2.1.5.1.2. Market
Forecast, 2022 – 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2021
9.2.1.5.2.2. Market
Forecast, 2022 – 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2021
9.2.1.5.3.2. Market
Forecast, 2022 – 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2021
9.2.1.5.4.2. Market
Forecast, 2022 – 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2021
9.2.1.5.5.2. Market
Forecast, 2022 – 2030
9.2.2. Gene Therapy
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2021
9.2.2.3. Market Forecast, 2022 – 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2021
9.2.2.5.1.2. Market
Forecast, 2022 – 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2021
9.2.2.5.2.2. Market
Forecast, 2022 – 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2021
9.2.2.5.3.2. Market
Forecast, 2022 – 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2021
9.2.2.5.4.2. Market
Forecast, 2022 – 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2021
9.2.2.5.5.2. Market
Forecast, 2022 – 2030
9.2.3. Immunotherapy
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2021
9.2.3.3. Market Forecast, 2022 – 2030
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2021
9.2.3.5.1.2. Market
Forecast, 2022 – 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2021
9.2.3.5.2.2. Market
Forecast, 2022 – 2030
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2021
9.2.3.5.3.2. Market
Forecast, 2022 – 2030
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2021
9.2.3.5.4.2. Market
Forecast, 2022 – 2030
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2021
9.2.3.5.5.2. Market
Forecast, 2022 – 2030
9.2.4. Stem Cell Therapy
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2021
9.2.4.3. Market Forecast, 2022 – 2030
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2021
9.2.4.5.1.2. Market
Forecast, 2022 – 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2021
9.2.4.5.2.2. Market
Forecast, 2022 – 2030
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2021
9.2.4.5.3.2. Market
Forecast, 2022 – 2030
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2021
9.2.4.5.4.2. Market
Forecast, 2022 – 2030
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2021
9.2.4.5.5.2. Market
Forecast, 2022 – 2030
9.2.5. Others
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2021
9.2.5.3. Market Forecast, 2022 – 2030
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2021
9.2.5.5.1.2. Market
Forecast, 2022 – 2030
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2021
9.2.5.5.2.2. Market
Forecast, 2022 – 2030
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2021
9.2.5.5.3.2. Market
Forecast, 2022 – 2030
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2021
9.2.5.5.4.2. Market
Forecast, 2022 – 2030
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2021
9.2.5.5.5.2. Market
Forecast, 2022 – 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By Therapy
10. Global Anti-Aging LongevityÂ
Market Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global
Anti-Aging Longevity Market Revenue (US$
Mn) and Forecasts, By Indication
10.2.1. Neurogenerative Diseases
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2021
10.2.1.3. Market Forecast, 2022 – 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2021
10.2.1.5.1.2. Market
Forecast, 2022 – 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2021
10.2.1.5.2.2. Market
Forecast, 2022 – 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2021
10.2.1.5.3.2. Market
Forecast, 2022 – 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2021
10.2.1.5.4.2. Market
Forecast, 2022 – 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2021
10.2.1.5.5.2. Market
Forecast, 2022 – 2030
10.2.2. Ophthalmic Conditions
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2021
10.2.2.3. Market Forecast, 2022 – 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2021
10.2.2.5.1.2. Market
Forecast, 2022 – 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2021
10.2.2.5.2.2. Market
Forecast, 2022 – 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2021
10.2.2.5.3.2. Market
Forecast, 2022 – 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2021
10.2.2.5.4.2. Market
Forecast, 2022 – 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2021
10.2.2.5.5.2. Market
Forecast, 2022 – 2030
10.2.3. Metabolic Diseases
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2021
10.2.3.3. Market Forecast, 2022 – 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2021
10.2.3.5.1.2. Market
Forecast, 2022 – 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2021
10.2.3.5.2.2. Market
Forecast, 2022 – 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2021
10.2.3.5.3.2. Market
Forecast, 2022 – 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2021
10.2.3.5.4.2. Market
Forecast, 2022 – 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2021
10.2.3.5.5.2. Market
Forecast, 2022 – 2030
10.2.4. Oncology
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2021
10.2.4.3. Market Forecast, 2022 – 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2021
10.2.4.5.1.2. Market
Forecast, 2022 – 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2021
10.2.4.5.2.2. Market
Forecast, 2022 – 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2021
10.2.4.5.3.2. Market
Forecast, 2022 – 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2021
10.2.4.5.4.2. Market
Forecast, 2022 – 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2021
10.2.4.5.5.2. Market
Forecast, 2022 – 2030
10.2.5. Tissue Homeostasis and Repair
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 - 2021
10.2.5.3. Market Forecast, 2022 – 2030
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market
Estimation, 2015 - 2021
10.2.5.5.1.2. Market
Forecast, 2022 – 2030
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 - 2021
10.2.5.5.2.2. Market
Forecast, 2022 – 2030
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market
Estimation, 2015 - 2021
10.2.5.5.3.2. Market
Forecast, 2022 – 2030
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 - 2021
10.2.5.5.4.2. Market
Forecast, 2022 – 2030
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market
Estimation, 2015 - 2021
10.2.5.5.5.2. Market
Forecast, 2022 – 2030
10.2.6. Cardio-vascular diseases
10.2.6.1. Definition
10.2.6.2. Market Estimation and Penetration, 2015 - 2021
10.2.6.3. Market Forecast, 2022 – 2030
10.2.6.4. Compound Annual Growth Rate (CAGR)
10.2.6.5. Regional Bifurcation
10.2.6.5.1. North America
10.2.6.5.1.1. Market
Estimation, 2015 - 2021
10.2.6.5.1.2. Market
Forecast, 2022 – 2030
10.2.6.5.2. Europe
10.2.6.5.2.1. Market
Estimation, 2015 - 2021
10.2.6.5.2.2. Market
Forecast, 2022 – 2030
10.2.6.5.3. Asia Pacific
10.2.6.5.3.1. Market
Estimation, 2015 - 2021
10.2.6.5.3.2. Market
Forecast, 2022 – 2030
10.2.6.5.4. Middle East and Africa
10.2.6.5.4.1. Market
Estimation, 2015 - 2021
10.2.6.5.4.2. Market
Forecast, 2022 – 2030
10.2.6.5.5. Latin America
10.2.6.5.5.1. Market
Estimation, 2015 - 2021
10.2.6.5.5.2. Market
Forecast, 2022 – 2030
10.2.7. Other
10.2.7.1. Definition
10.2.7.2. Market Estimation and Penetration, 2015 - 2021
10.2.7.3. Market Forecast, 2022 – 2030
10.2.7.4. Compound Annual Growth Rate (CAGR)
10.2.7.5. Regional Bifurcation
10.2.7.5.1. North America
10.2.7.5.1.1. Market
Estimation, 2015 - 2021
10.2.7.5.1.2. Market
Forecast, 2022 – 2030
10.2.7.5.2. Europe
10.2.7.5.2.1. Market
Estimation, 2015 - 2021
10.2.7.5.2.2. Market
Forecast, 2022 – 2030
10.2.7.5.3. Asia Pacific
10.2.7.5.3.1. Market
Estimation, 2015 - 2021
10.2.7.5.3.2. Market
Forecast, 2022 – 2030
10.2.7.5.4. Middle East and Africa
10.2.7.5.4.1. Market
Estimation, 2015 - 2021
10.2.7.5.4.2. Market
Forecast, 2022 – 2030
10.2.7.5.5. Latin America
10.2.7.5.5.1. Market
Estimation, 2015 - 2021
10.2.7.5.5.2. Market
Forecast, 2022 – 2030
10.3. Key
Segment for Channeling Investments
10.3.1. By Indication
11. Global Anti-Aging LongevityÂ
Market Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.2. Global
Anti-Aging Longevity Market Revenue (US$
Mn) and Forecasts, By End user
11.2.1. Hospital and Clinics
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2021
11.2.1.3. Market Forecast, 2022 – 2030
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 - 2021
11.2.1.5.1.2. Market
Forecast, 2022 – 2030
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 - 2021
11.2.1.5.2.2. Market
Forecast, 2022 – 2030
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 - 2021
11.2.1.5.3.2. Market
Forecast, 2022 – 2030
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 - 2021
11.2.1.5.4.2. Market
Forecast, 2022 – 2030
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 - 2021
11.2.1.5.5.2. Market
Forecast, 2022 – 2030
11.2.2. Academic and Research Institutions
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2021
11.2.2.3. Market Forecast, 2022 – 2030
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 - 2021
11.2.2.5.1.2. Market
Forecast, 2022 – 2030
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 - 2021
11.2.2.5.2.2. Market
Forecast, 2022 – 2030
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 - 2021
11.2.2.5.3.2. Market
Forecast, 2022 – 2030
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 - 2021
11.2.2.5.4.2. Market
Forecast, 2022 – 2030
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 - 2021
11.2.2.5.5.2. Market
Forecast, 2022 – 2030
11.2.3. Others
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 - 2021
11.2.3.3. Market Forecast, 2022 – 2030
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 - 2021
11.2.3.5.1.2. Market
Forecast, 2022 – 2030
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 - 2021
11.2.3.5.2.2. Market
Forecast, 2022 – 2030
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 - 2021
11.2.3.5.3.2. Market
Forecast, 2022 – 2030
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 - 2021
11.2.3.5.4.2. Market
Forecast, 2022 – 2030
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 - 2021
11.2.3.5.5.2. Market
Forecast, 2022 – 2030
11.3. Key
Segment for Channeling Investments
11.3.1. By End user
12. North America Anti-Aging Longevity Market Analysis and Forecasts, 2022 – 2030
12.1. Overview
12.1.1. North America Anti-Aging Longevity Market Revenue (US$ Mn)
12.2. North
America Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
12.2.1. Research and Pre-Clinical
12.2.2. Phase I
12.2.3. Phase II
12.2.4. Phase III
12.3. North
America Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, By Therapy
12.3.1. Senolytic Drug Therapy
12.3.2. Gene Therapy
12.3.3. Immunotherapy
12.3.4. Stem Cell Therapy
12.3.5. Others
12.4. North
America Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, ByÂ
Indication
12.4.1. Neurogenerative Diseases
12.4.2. Ophthalmic Conditions
12.4.3. Metabolic Diseases
12.4.4. Oncology
12.4.5. Tissue Homeostasis and Repair
12.4.6. Cardio-vascular diseases
12.4.7. Other
12.5. North
America Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, By End user
12.5.1. Hospital and Clinics
12.5.2. Academic and Research Institutions
12.5.3. Others
12.6. North
America Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
12.6.1.1.1. Research and Pre-Clinical
12.6.1.1.2. Phase I
12.6.1.1.3. Phase II
12.6.1.1.4. Phase III
12.6.1.2. U.S Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
12.6.1.2.1. Senolytic Drug Therapy
12.6.1.2.2. Gene Therapy
12.6.1.2.3. Immunotherapy
12.6.1.2.4. Stem Cell Therapy
12.6.1.2.5. Others
12.6.1.3. U.S Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
12.6.1.3.1. Neurogenerative Diseases
12.6.1.3.2. Ophthalmic Conditions
12.6.1.3.3. Metabolic Diseases
12.6.1.3.4. Oncology
12.6.1.3.5. Tissue Homeostasis and Repair
12.6.1.3.6. Cardio-vascular diseases
12.6.1.3.7. Other
12.6.1.4. U.S Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
12.6.1.4.1. Hospital and Clinics
12.6.1.4.2. Academic and Research Institutions
12.6.1.4.3. Others
12.6.2. Canada
12.6.2.1. Canada Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
12.6.2.1.1. Research and Pre-Clinical
12.6.2.1.2. Phase I
12.6.2.1.3. Phase II
12.6.2.1.4. Phase III
12.6.2.2. Canada Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
12.6.2.2.1. Senolytic Drug Therapy
12.6.2.2.2. Gene Therapy
12.6.2.2.3. Immunotherapy
12.6.2.2.4. Stem Cell Therapy
12.6.2.2.5. Others
12.6.2.3. Canada Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
12.6.2.3.1. Neurogenerative Diseases
12.6.2.3.2. Ophthalmic Conditions
12.6.2.3.3. Metabolic Diseases
12.6.2.3.4. Oncology
12.6.2.3.5. Tissue Homeostasis and Repair
12.6.2.3.6. Cardio-vascular diseases
12.6.2.3.7. Other
12.6.2.4. Canada Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
12.6.2.4.1. Hospital and Clinics
12.6.2.4.2. Academic and Research Institutions
12.6.2.4.3. Others
12.6.3. Mexico
12.6.3.1. Mexico Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
12.6.3.1.1. Research and Pre-Clinical
12.6.3.1.2. Phase I
12.6.3.1.3. Phase II
12.6.3.1.4. Phase III
12.6.3.2. Mexico Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
12.6.3.2.1. Senolytic Drug Therapy
12.6.3.2.2. Gene Therapy
12.6.3.2.3. Immunotherapy
12.6.3.2.4. Stem Cell Therapy
12.6.3.2.5. Others
12.6.3.3. Mexico Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
12.6.3.3.1. Neurogenerative Diseases
12.6.3.3.2. Ophthalmic Conditions
12.6.3.3.3. Metabolic Diseases
12.6.3.3.4. Oncology
12.6.3.3.5. Tissue Homeostasis and Repair
12.6.3.3.6. Cardio-vascular diseases
12.6.3.3.7. Other
12.6.3.4. Mexico Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
12.6.3.4.1. Hospital and Clinics
12.6.3.4.2. Academic and Research Institutions
12.6.3.4.3. Others
12.6.4. Rest of North America
12.6.4.1. Rest of North America Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Clinical Phases
12.6.4.1.1. Research and Pre-Clinical
12.6.4.1.2. Phase I
12.6.4.1.3. Phase II
12.6.4.1.4. Phase III
12.6.4.2. Rest of North America Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Therapy
12.6.4.2.1. Senolytic Drug Therapy
12.6.4.2.2. Gene Therapy
12.6.4.2.3. Immunotherapy
12.6.4.2.4. Stem Cell Therapy
12.6.4.2.5. Others
12.6.4.3. Rest of North America Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts,
By Indication
12.6.4.3.1. Neurogenerative Diseases
12.6.4.3.2. Ophthalmic Conditions
12.6.4.3.3. Metabolic Diseases
12.6.4.3.4. Oncology
12.6.4.3.5. Tissue Homeostasis and Repair
12.6.4.3.6. Cardio-vascular diseases
12.6.4.3.7. Other
12.6.4.4. Rest of North America Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By End
user
12.6.4.4.1. Hospital and Clinics
12.6.4.4.2. Academic and Research Institutions
12.6.4.4.3. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Clinical Phases
12.7.3. By Therapy
12.7.4. By Indication
12.7.5. By End user
13. Europe Anti-Aging LongevityÂ
Market Analysis and Forecasts, 2022 – 2030
13.1. Overview
13.1.1. Europe Anti-Aging LongevityÂ
Market Revenue (US$ Mn)
13.2. Europe
Anti-Aging Longevity Market Revenue (US$
Mn) and Forecasts, By Clinical Phases
13.2.1. Research and Pre-Clinical
13.2.2. Phase I
13.2.3. Phase II
13.2.4. Phase III
13.3. Europe
Anti-Aging Longevity Market Revenue (US$
Mn) and Forecasts, By Therapy
13.3.1. Senolytic Drug Therapy
13.3.2. Gene Therapy
13.3.3. Immunotherapy
13.3.4. Stem Cell Therapy
13.3.5. Others
13.4. Europe
Anti-Aging Longevity Market Revenue (US$
Mn) and Forecasts, By Indication
13.4.1. Neurogenerative Diseases
13.4.2. Ophthalmic Conditions
13.4.3. Metabolic Diseases
13.4.4. Oncology
13.4.5. Tissue Homeostasis and Repair
13.4.6. Cardio-vascular diseases
13.4.7. Other
13.5. Europe
Anti-Aging Longevity Market Revenue (US$
Mn) and Forecasts, By End user
13.5.1. Hospital and Clinics
13.5.2. Academic and Research Institutions
13.5.3. Others
13.6. Europe
Anti-Aging Longevity Market Revenue (US$
Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
13.6.1.1.1. Research and Pre-Clinical
13.6.1.1.2. Phase I
13.6.1.1.3. Phase II
13.6.1.1.4. Phase III
13.6.1.2. France Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
13.6.1.2.1. Senolytic Drug Therapy
13.6.1.2.2. Gene Therapy
13.6.1.2.3. Immunotherapy
13.6.1.2.4. Stem Cell Therapy
13.6.1.2.5. Others
13.6.1.3. France Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
13.6.1.3.1. Neurogenerative Diseases
13.6.1.3.2. Ophthalmic Conditions
13.6.1.3.3. Metabolic Diseases
13.6.1.3.4. Oncology
13.6.1.3.5. Tissue Homeostasis and Repair
13.6.1.3.6. Cardio-vascular diseases
13.6.1.3.7. Other
13.6.1.4. France Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
13.6.1.4.1. Hospital and Clinics
13.6.1.4.2. Academic and Research Institutions
13.6.1.4.3. Others
13.6.2. The UK
13.6.2.1. The UK Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
13.6.2.1.1. Research and Pre-Clinical
13.6.2.1.2. Phase I
13.6.2.1.3. Phase II
13.6.2.1.4. Phase III
13.6.2.2. The UK Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
13.6.2.2.1. Senolytic Drug Therapy
13.6.2.2.2. Gene Therapy
13.6.2.2.3. Immunotherapy
13.6.2.2.4. Stem Cell Therapy
13.6.2.2.5. Others
13.6.2.3. The UK Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
13.6.2.3.1. Neurogenerative Diseases
13.6.2.3.2. Ophthalmic Conditions
13.6.2.3.3. Metabolic Diseases
13.6.2.3.4. Oncology
13.6.2.3.5. Tissue Homeostasis and Repair
13.6.2.3.6. Cardio-vascular diseases
13.6.2.3.7. Other
13.6.2.4. The UK Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
13.6.2.4.1. Hospital and Clinics
13.6.2.4.2. Academic and Research Institutions
13.6.2.4.3. Others
13.6.3. Spain
13.6.3.1. Spain Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
13.6.3.1.1. Research and Pre-Clinical
13.6.3.1.2. Phase I
13.6.3.1.3. Phase II
13.6.3.1.4. Phase III
13.6.3.2. Spain Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
13.6.3.2.1. Senolytic Drug Therapy
13.6.3.2.2. Gene Therapy
13.6.3.2.3. Immunotherapy
13.6.3.2.4. Stem Cell Therapy
13.6.3.2.5. Others
13.6.3.3. Spain Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
13.6.3.3.1. Neurogenerative Diseases
13.6.3.3.2. Ophthalmic Conditions
13.6.3.3.3. Metabolic Diseases
13.6.3.3.4. Oncology
13.6.3.3.5. Tissue Homeostasis and Repair
13.6.3.3.6. Cardio-vascular diseases
13.6.3.3.7. Other
13.6.3.4. Spain Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
13.6.3.4.1. Hospital and Clinics
13.6.3.4.2. Academic and Research Institutions
13.6.3.4.3. Others
13.6.4. Germany
13.6.4.1. Germany Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
13.6.4.1.1. Research and Pre-Clinical
13.6.4.1.2. Phase I
13.6.4.1.3. Phase II
13.6.4.1.4. Phase III
13.6.4.2. Germany Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
13.6.4.2.1. Senolytic Drug Therapy
13.6.4.2.2. Gene Therapy
13.6.4.2.3. Immunotherapy
13.6.4.2.4. Stem Cell Therapy
13.6.4.2.5. Others
13.6.4.3. Germany Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
13.6.4.3.1. Neurogenerative Diseases
13.6.4.3.2. Ophthalmic Conditions
13.6.4.3.3. Metabolic Diseases
13.6.4.3.4. Oncology
13.6.4.3.5. Tissue Homeostasis and Repair
13.6.4.3.6. Cardio-vascular diseases
13.6.4.3.7. Other
13.6.4.4. Germany Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
13.6.4.4.1. Hospital and Clinics
13.6.4.4.2. Academic and Research Institutions
13.6.4.4.3. Others
13.6.5. Italy
13.6.5.1. Italy Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
13.6.5.1.1. Research and Pre-Clinical
13.6.5.1.2. Phase I
13.6.5.1.3. Phase II
13.6.5.1.4. Phase III
13.6.5.2. Italy Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
13.6.5.2.1. Senolytic Drug Therapy
13.6.5.2.2. Gene Therapy
13.6.5.2.3. Immunotherapy
13.6.5.2.4. Stem Cell Therapy
13.6.5.2.5. Others
13.6.5.3. Italy Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
13.6.5.3.1. Neurogenerative Diseases
13.6.5.3.2. Ophthalmic Conditions
13.6.5.3.3. Metabolic Diseases
13.6.5.3.4. Oncology
13.6.5.3.5. Tissue Homeostasis and Repair
13.6.5.3.6. Cardio-vascular diseases
13.6.5.3.7. Other
13.6.5.4. Italy Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
13.6.5.4.1. Hospital and Clinics
13.6.5.4.2. Academic and Research Institutions
13.6.5.4.3. Others
13.6.6. Nordic Countries
13.6.6.1. Nordic Countries Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Clinical Phases
13.6.6.1.1. Research and Pre-Clinical
13.6.6.1.2. Phase I
13.6.6.1.3. Phase II
13.6.6.1.4. Phase III
13.6.6.2. Nordic Countries Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Therapy
13.6.6.2.1. Senolytic Drug Therapy
13.6.6.2.2. Gene Therapy
13.6.6.2.3. Immunotherapy
13.6.6.2.4. Stem Cell Therapy
13.6.6.2.5. Others
13.6.6.3. Nordic Countries Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts,
By Indication
13.6.6.3.1. Neurogenerative Diseases
13.6.6.3.2. Ophthalmic Conditions
13.6.6.3.3. Metabolic Diseases
13.6.6.3.4. Oncology
13.6.6.3.5. Tissue Homeostasis and Repair
13.6.6.3.6. Cardio-vascular diseases
13.6.6.3.7. Other
13.6.6.4. Nordic Countries Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By End
user
13.6.6.4.1. Hospital and Clinics
13.6.6.4.2. Academic and Research Institutions
13.6.6.4.3. Others
13.6.6.5. Nordic Countries Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux Union
13.6.7.1. Benelux Union Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Clinical Phases
13.6.7.1.1. Research and Pre-Clinical
13.6.7.1.2. Phase I
13.6.7.1.3. Phase II
13.6.7.1.4. Phase III
13.6.7.2. Benelux Union Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Therapy
13.6.7.2.1. Senolytic Drug Therapy
13.6.7.2.2. Gene Therapy
13.6.7.2.3. Immunotherapy
13.6.7.2.4. Stem Cell Therapy
13.6.7.2.5. Others
13.6.7.3. Benelux Union Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts,
By Indication
13.6.7.3.1. Neurogenerative Diseases
13.6.7.3.2. Ophthalmic Conditions
13.6.7.3.3. Metabolic Diseases
13.6.7.3.4. Oncology
13.6.7.3.5. Tissue Homeostasis and Repair
13.6.7.3.6. Cardio-vascular diseases
13.6.7.3.7. Other
13.6.7.4. Benelux Union Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By End
user
13.6.7.4.1. Hospital and Clinics
13.6.7.4.2. Academic and Research Institutions
13.6.7.4.3. Others
13.6.7.5. Benelux Union Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of Europe
13.6.8.1. Rest of Europe Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Clinical Phases
13.6.8.1.1. Research and Pre-Clinical
13.6.8.1.2. Phase I
13.6.8.1.3. Phase II
13.6.8.1.4. Phase III
13.6.8.2. Rest of Europe Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Therapy
13.6.8.2.1. Senolytic Drug Therapy
13.6.8.2.2. Gene Therapy
13.6.8.2.3. Immunotherapy
13.6.8.2.4. Stem Cell Therapy
13.6.8.2.5. Others
13.6.8.3. Rest of Europe Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts,
By Indication
13.6.8.3.1. Neurogenerative Diseases
13.6.8.3.2. Ophthalmic Conditions
13.6.8.3.3. Metabolic Diseases
13.6.8.3.4. Oncology
13.6.8.3.5. Tissue Homeostasis and Repair
13.6.8.3.6. Cardio-vascular diseases
13.6.8.3.7. Other
13.6.8.4. Rest of Europe Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By End
user
13.6.8.4.1. Hospital and Clinics
13.6.8.4.2. Academic and Research Institutions
13.6.8.4.3. Others
13.7. Key
Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Clinical Phases
13.7.3. By Therapy
13.7.4. By Indication
13.7.5. By End user
14. Asia Pacific Anti-Aging Longevity Market Analysis and Forecasts, 2022 – 2030
14.1. Overview
14.1.1. Asia Pacific Anti-Aging Longevity Market Revenue (US$ Mn)
14.2. Asia
Pacific Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
14.2.1. Research and Pre-Clinical
14.2.2. Phase I
14.2.3. Phase II
14.2.4. Phase III
14.3. Asia
Pacific Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, By Therapy
14.3.1. Senolytic Drug Therapy
14.3.2. Gene Therapy
14.3.3. Immunotherapy
14.3.4. Stem Cell Therapy
14.3.5. Others
14.4. Asia
Pacific Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, ByÂ
Indication
14.4.1. Neurogenerative Diseases
14.4.2. Ophthalmic Conditions
14.4.3. Metabolic Diseases
14.4.4. Oncology
14.4.5. Tissue Homeostasis and Repair
14.4.6. Cardio-vascular diseases
14.4.7. Other
14.5. Asia
Pacific Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, By End user
14.5.1. Hospital and Clinics
14.5.2. Academic and Research Institutions
14.5.3. Others
14.6. Asia
Pacific Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
14.6.1.1.1. Research and Pre-Clinical
14.6.1.1.2. Phase I
14.6.1.1.3. Phase II
14.6.1.1.4. Phase III
14.6.1.2. China Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
14.6.1.2.1. Senolytic Drug Therapy
14.6.1.2.2. Gene Therapy
14.6.1.2.3. Immunotherapy
14.6.1.2.4. Stem Cell Therapy
14.6.1.2.5. Others
14.6.1.3. China Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
14.6.1.3.1. Neurogenerative Diseases
14.6.1.3.2. Ophthalmic Conditions
14.6.1.3.3. Metabolic Diseases
14.6.1.3.4. Oncology
14.6.1.3.5. Tissue Homeostasis and Repair
14.6.1.3.6. Cardio-vascular diseases
14.6.1.3.7. Other
14.6.1.4. China Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
14.6.1.4.1. Hospital and Clinics
14.6.1.4.2. Academic and Research Institutions
14.6.1.4.3. Others
14.6.2. Japan
14.6.2.1. Japan Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
14.6.2.1.1. Research and Pre-Clinical
14.6.2.1.2. Phase I
14.6.2.1.3. Phase II
14.6.2.1.4. Phase III
14.6.2.2. Japan Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
14.6.2.2.1. Senolytic Drug Therapy
14.6.2.2.2. Gene Therapy
14.6.2.2.3. Immunotherapy
14.6.2.2.4. Stem Cell Therapy
14.6.2.2.5. Others
14.6.2.3. Japan Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
14.6.2.3.1. Neurogenerative Diseases
14.6.2.3.2. Ophthalmic Conditions
14.6.2.3.3. Metabolic Diseases
14.6.2.3.4. Oncology
14.6.2.3.5. Tissue Homeostasis and Repair
14.6.2.3.6. Cardio-vascular diseases
14.6.2.3.7. Other
14.6.2.4. Japan Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
14.6.2.4.1. Hospital and Clinics
14.6.2.4.2. Academic and Research Institutions
14.6.2.4.3. Others
14.6.3. India
14.6.3.1. India Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
14.6.3.1.1. Research and Pre-Clinical
14.6.3.1.2. Phase I
14.6.3.1.3. Phase II
14.6.3.1.4. Phase III
14.6.3.2. India Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
14.6.3.2.1. Senolytic Drug Therapy
14.6.3.2.2. Gene Therapy
14.6.3.2.3. Immunotherapy
14.6.3.2.4. Stem Cell Therapy
14.6.3.2.5. Others
14.6.3.3. India Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
14.6.3.3.1. Neurogenerative Diseases
14.6.3.3.2. Ophthalmic Conditions
14.6.3.3.3. Metabolic Diseases
14.6.3.3.4. Oncology
14.6.3.3.5. Tissue Homeostasis and Repair
14.6.3.3.6. Cardio-vascular diseases
14.6.3.3.7. Other
14.6.3.4. India Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
14.6.3.4.1. Hospital and Clinics
14.6.3.4.2. Academic and Research Institutions
14.6.3.4.3. Others
14.6.4. New Zealand
14.6.4.1. New Zealand Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Clinical Phases
14.6.4.1.1. Research and Pre-Clinical
14.6.4.1.2. Phase I
14.6.4.1.3. Phase II
14.6.4.1.4. Phase III
14.6.4.2. New Zealand Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Therapy
14.6.4.2.1. Senolytic Drug Therapy
14.6.4.2.2. Gene Therapy
14.6.4.2.3. Immunotherapy
14.6.4.2.4. Stem Cell Therapy
14.6.4.2.5. Others
14.6.4.3. New Zealand Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts,
By Indication
14.6.4.3.1. Neurogenerative Diseases
14.6.4.3.2. Ophthalmic Conditions
14.6.4.3.3. Metabolic Diseases
14.6.4.3.4. Oncology
14.6.4.3.5. Tissue Homeostasis and Repair
14.6.4.3.6. Cardio-vascular diseases
14.6.4.3.7. Other
14.6.4.4. New Zealand Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By End
user
14.6.4.4.1. Hospital and Clinics
14.6.4.4.2. Academic and Research Institutions
14.6.4.4.3. Others
14.6.5. Australia
14.6.5.1. Australia Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
14.6.5.1.1. Research and Pre-Clinical
14.6.5.1.2. Phase I
14.6.5.1.3. Phase II
14.6.5.1.4. Phase III
14.6.5.2. Australia Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
14.6.5.2.1. Senolytic Drug Therapy
14.6.5.2.2. Gene Therapy
14.6.5.2.3. Immunotherapy
14.6.5.2.4. Stem Cell Therapy
14.6.5.2.5. Others
14.6.5.3. Australia Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
14.6.5.3.1. Neurogenerative Diseases
14.6.5.3.2. Ophthalmic Conditions
14.6.5.3.3. Metabolic Diseases
14.6.5.3.4. Oncology
14.6.5.3.5. Tissue Homeostasis and Repair
14.6.5.3.6. Cardio-vascular diseases
14.6.5.3.7. Other
14.6.5.4. Australia Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
14.6.5.4.1. Hospital and Clinics
14.6.5.4.2. Academic and Research Institutions
14.6.5.4.3. Others
14.6.6. South Korea
14.6.6.1. South Korea Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Clinical Phases
14.6.6.1.1. Research and Pre-Clinical
14.6.6.1.2. Phase I
14.6.6.1.3. Phase II
14.6.6.1.4. Phase III
14.6.6.2. South Korea Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Therapy
14.6.6.2.1. Senolytic Drug Therapy
14.6.6.2.2. Gene Therapy
14.6.6.2.3. Immunotherapy
14.6.6.2.4. Stem Cell Therapy
14.6.6.2.5. Others
14.6.6.3. South Korea Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts,
By Indication
14.6.6.3.1. Neurogenerative Diseases
14.6.6.3.2. Ophthalmic Conditions
14.6.6.3.3. Metabolic Diseases
14.6.6.3.4. Oncology
14.6.6.3.5. Tissue Homeostasis and Repair
14.6.6.3.6. Cardio-vascular diseases
14.6.6.3.7. Other
14.6.6.4. South Korea Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By End
user
14.6.6.4.1. Hospital and Clinics
14.6.6.4.2. Academic and Research Institutions
14.6.6.4.3. Others
14.6.7. Southeast Asia
14.6.7.1. Southeast Asia Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Clinical Phases
14.6.7.1.1. Research and Pre-Clinical
14.6.7.1.2. Phase I
14.6.7.1.3. Phase II
14.6.7.1.4. Phase III
14.6.7.2. Southeast Asia Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Therapy
14.6.7.2.1. Senolytic Drug Therapy
14.6.7.2.2. Gene Therapy
14.6.7.2.3. Immunotherapy
14.6.7.2.4. Stem Cell Therapy
14.6.7.2.5. Others
14.6.7.3. Southeast Asia Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts,
By Indication
14.6.7.3.1. Neurogenerative Diseases
14.6.7.3.2. Ophthalmic Conditions
14.6.7.3.3. Metabolic Diseases
14.6.7.3.4. Oncology
14.6.7.3.5. Tissue Homeostasis and Repair
14.6.7.3.6. Cardio-vascular diseases
14.6.7.3.7. Other
14.6.7.4. Southeast Asia Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By End
user
14.6.7.4.1. Hospital and Clinics
14.6.7.4.2. Academic and Research Institutions
14.6.7.4.3. Others
14.6.7.5. Southeast Asia Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1. Rest of Asia Pacific Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Clinical Phases
14.6.8.1.1. Research and Pre-Clinical
14.6.8.1.2. Phase I
14.6.8.1.3. Phase II
14.6.8.1.4. Phase III
14.6.8.2. Rest of Asia Pacific Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Therapy
14.6.8.2.1. Senolytic Drug Therapy
14.6.8.2.2. Gene Therapy
14.6.8.2.3. Immunotherapy
14.6.8.2.4. Stem Cell Therapy
14.6.8.2.5. Others
14.6.8.3. Rest of Asia Pacific Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts,
By Indication
14.6.8.3.1. Neurogenerative Diseases
14.6.8.3.2. Ophthalmic Conditions
14.6.8.3.3. Metabolic Diseases
14.6.8.3.4. Oncology
14.6.8.3.5. Tissue Homeostasis and Repair
14.6.8.3.6. Cardio-vascular diseases
14.6.8.3.7. Other
14.6.8.4. Rest of Asia Pacific Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By End
user
14.6.8.4.1. Hospital and Clinics
14.6.8.4.2. Academic and Research Institutions
14.6.8.4.3. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Clinical Phases
14.7.3. By Therapy
14.7.4. By Indication
14.7.5. By End user
15. Middle East and Africa Anti-Aging Longevity Market Analysis and Forecasts, 2022 – 2030
15.1. Overview
15.1.1. Middle East and Africa Anti-Aging Longevity Market Revenue (US$ Mn)
15.2. Middle
East and Africa Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
15.2.1. Research and Pre-Clinical
15.2.2. Phase I
15.2.3. Phase II
15.2.4. Phase III
15.3. Middle
East and Africa Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
15.3.1. Senolytic Drug Therapy
15.3.2. Gene Therapy
15.3.3. Immunotherapy
15.3.4. Stem Cell Therapy
15.3.5. Others
15.4. Middle
East and Africa Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
15.4.1. Neurogenerative Diseases
15.4.2. Ophthalmic Conditions
15.4.3. Metabolic Diseases
15.4.4. Oncology
15.4.5. Tissue Homeostasis and Repair
15.4.6. Cardio-vascular diseases
15.4.7. Other
15.5. Middle
East and Africa Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
15.5.1. Hospital and Clinics
15.5.2. Academic and Research Institutions
15.5.3. Others
15.6. Middle
East and Africa Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1. Saudi Arabia Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Clinical Phases
15.6.1.1.1. Research and Pre-Clinical
15.6.1.1.2. Phase I
15.6.1.1.3. Phase II
15.6.1.1.4. Phase III
15.6.1.2. Saudi Arabia Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Therapy
15.6.1.2.1. Senolytic Drug Therapy
15.6.1.2.2. Gene Therapy
15.6.1.2.3. Immunotherapy
15.6.1.2.4. Stem Cell Therapy
15.6.1.2.5. Others
15.6.1.3. Saudi Arabia Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts,
By Indication
15.6.1.3.1. Neurogenerative Diseases
15.6.1.3.2. Ophthalmic Conditions
15.6.1.3.3. Metabolic Diseases
15.6.1.3.4. Oncology
15.6.1.3.5. Tissue Homeostasis and Repair
15.6.1.3.6. Cardio-vascular diseases
15.6.1.3.7. Other
15.6.1.4. Saudi Arabia Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By End
user
15.6.1.4.1. Hospital and Clinics
15.6.1.4.2. Academic and Research Institutions
15.6.1.4.3. Others
15.6.2. UAE
15.6.2.1. UAE Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
15.6.2.1.1. Research and Pre-Clinical
15.6.2.1.2. Phase I
15.6.2.1.3. Phase II
15.6.2.1.4. Phase III
15.6.2.2. UAE Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
15.6.2.2.1. Senolytic Drug Therapy
15.6.2.2.2. Gene Therapy
15.6.2.2.3. Immunotherapy
15.6.2.2.4. Stem Cell Therapy
15.6.2.2.5. Others
15.6.2.3. UAE Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
15.6.2.3.1. Neurogenerative Diseases
15.6.2.3.2. Ophthalmic Conditions
15.6.2.3.3. Metabolic Diseases
15.6.2.3.4. Oncology
15.6.2.3.5. Tissue Homeostasis and Repair
15.6.2.3.6. Cardio-vascular diseases
15.6.2.3.7. Other
15.6.2.4. UAE Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
15.6.2.4.1. Hospital and Clinics
15.6.2.4.2. Academic and Research Institutions
15.6.2.4.3. Others
15.6.3. Egypt
15.6.3.1. Egypt Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
15.6.3.1.1. Research and Pre-Clinical
15.6.3.1.2. Phase I
15.6.3.1.3. Phase II
15.6.3.1.4. Phase III
15.6.3.2. Egypt Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
15.6.3.2.1. Senolytic Drug Therapy
15.6.3.2.2. Gene Therapy
15.6.3.2.3. Immunotherapy
15.6.3.2.4. Stem Cell Therapy
15.6.3.2.5. Others
15.6.3.3. Egypt Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
15.6.3.3.1. Neurogenerative Diseases
15.6.3.3.2. Ophthalmic Conditions
15.6.3.3.3. Metabolic Diseases
15.6.3.3.4. Oncology
15.6.3.3.5. Tissue Homeostasis and Repair
15.6.3.3.6. Cardio-vascular diseases
15.6.3.3.7. Other
15.6.3.4. Egypt Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
15.6.3.4.1. Hospital and Clinics
15.6.3.4.2. Academic and Research Institutions
15.6.3.4.3. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
15.6.4.1.1. Research and Pre-Clinical
15.6.4.1.2. Phase I
15.6.4.1.3. Phase II
15.6.4.1.4. Phase III
15.6.4.2. Kuwait Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
15.6.4.2.1. Senolytic Drug Therapy
15.6.4.2.2. Gene Therapy
15.6.4.2.3. Immunotherapy
15.6.4.2.4. Stem Cell Therapy
15.6.4.2.5. Others
15.6.4.3. Kuwait Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
15.6.4.3.1. Neurogenerative Diseases
15.6.4.3.2. Ophthalmic Conditions
15.6.4.3.3. Metabolic Diseases
15.6.4.3.4. Oncology
15.6.4.3.5. Tissue Homeostasis and Repair
15.6.4.3.6. Cardio-vascular diseases
15.6.4.3.7. Other
15.6.4.4. Kuwait Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
15.6.4.4.1. Hospital and Clinics
15.6.4.4.2. Academic and Research Institutions
15.6.4.4.3. Others
15.6.5. South Africa
15.6.5.1. South Africa Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Clinical Phases
15.6.5.1.1. Research and Pre-Clinical
15.6.5.1.2. Phase I
15.6.5.1.3. Phase II
15.6.5.1.4. Phase III
15.6.5.2. South Africa Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Therapy
15.6.5.2.1. Senolytic Drug Therapy
15.6.5.2.2. Gene Therapy
15.6.5.2.3. Immunotherapy
15.6.5.2.4. Stem Cell Therapy
15.6.5.2.5. Others
15.6.5.3. South Africa Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts,
By Indication
15.6.5.3.1. Neurogenerative Diseases
15.6.5.3.2. Ophthalmic Conditions
15.6.5.3.3. Metabolic Diseases
15.6.5.3.4. Oncology
15.6.5.3.5. Tissue Homeostasis and Repair
15.6.5.3.6. Cardio-vascular diseases
15.6.5.3.7. Other
15.6.5.4. South Africa Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By End
user
15.6.5.4.1. Hospital and Clinics
15.6.5.4.2. Academic and Research Institutions
15.6.5.4.3. Others
15.6.6. Rest of Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Clinical Phases
15.6.6.1.1. Research and Pre-Clinical
15.6.6.1.2. Phase I
15.6.6.1.3. Phase II
15.6.6.1.4. Phase III
15.6.6.2. Rest of Middle East & Africa Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Therapy
15.6.6.2.1. Senolytic Drug Therapy
15.6.6.2.2. Gene Therapy
15.6.6.2.3. Immunotherapy
15.6.6.2.4. Stem Cell Therapy
15.6.6.2.5. Others
15.6.6.3. Rest of Middle East & Africa Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts,
By Indication
15.6.6.3.1. Neurogenerative Diseases
15.6.6.3.2. Ophthalmic Conditions
15.6.6.3.3. Metabolic Diseases
15.6.6.3.4. Oncology
15.6.6.3.5. Tissue Homeostasis and Repair
15.6.6.3.6. Cardio-vascular diseases
15.6.6.3.7. Other
15.6.6.4. Rest of Middle East & Africa Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By End
user
15.6.6.4.1. Hospital and Clinics
15.6.6.4.2. Academic and Research Institutions
15.6.6.4.3. Others
15.7. Key
Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Clinical Phases
15.7.3. By Therapy
15.7.4. By Indication
15.7.5. By End user
16. Latin America Anti-Aging Longevity Market Analysis and Forecasts, 2022 – 2030
16.1. Overview
16.1.1. Latin America Anti-Aging Longevity Market Revenue (US$ Mn)
16.2. Latin
America Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, By Clinical Phases
16.2.1. Research and Pre-Clinical
16.2.2. Phase I
16.2.3. Phase II
16.2.4. Phase III
16.3. Latin
America Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, By Therapy
16.3.1. Senolytic Drug Therapy
16.3.2. Gene Therapy
16.3.3. Immunotherapy
16.3.4. Stem Cell Therapy
16.3.5. Others
16.4. Latin
America Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, ByÂ
Indication
16.4.1. Neurogenerative Diseases
16.4.2. Ophthalmic Conditions
16.4.3. Metabolic Diseases
16.4.4. Oncology
16.4.5. Tissue Homeostasis and Repair
16.4.6. Cardio-vascular diseases
16.4.7. Other
16.5. Latin
America Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, By End user
16.5.1. Hospital and Clinics
16.5.2. Academic and Research Institutions
16.5.3. Others
16.6. Latin
America Anti-Aging Longevity Market
Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Clinical Phases
16.6.1.1.1. Research and Pre-Clinical
16.6.1.1.2. Phase I
16.6.1.1.3. Phase II
16.6.1.1.4. Phase III
16.6.1.2. Brazil Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
16.6.1.2.1. Senolytic Drug Therapy
16.6.1.2.2. Gene Therapy
16.6.1.2.3. Immunotherapy
16.6.1.2.4. Stem Cell Therapy
16.6.1.2.5. Others
16.6.1.3. Brazil Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
16.6.1.3.1. Neurogenerative Diseases
16.6.1.3.2. Ophthalmic Conditions
16.6.1.3.3. Metabolic Diseases
16.6.1.3.4. Oncology
16.6.1.3.5. Tissue Homeostasis and Repair
16.6.1.3.6. Cardio-vascular diseases
16.6.1.3.7. Other
16.6.1.4. Brazil Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
16.6.1.4.1. Hospital and Clinics
16.6.1.4.2. Academic and Research Institutions
16.6.1.4.3. Others
16.6.2. Argentina
16.6.2.1. Argentina Anti-Aging Longevity  Market Revenue (US$ Mn) and Forecasts, By
Clinical Phases
16.6.2.1.1. Research and Pre-Clinical
16.6.2.1.2. Phase I
16.6.2.1.3. Phase II
16.6.2.1.4. Phase III
16.6.2.2. Argentina Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Therapy
16.6.2.2.1. Senolytic Drug Therapy
16.6.2.2.2. Gene Therapy
16.6.2.2.3. Immunotherapy
16.6.2.2.4. Stem Cell Therapy
16.6.2.2.5. Others
16.6.2.3. Argentina Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By Indication
16.6.2.3.1. Neurogenerative Diseases
16.6.2.3.2. Ophthalmic Conditions
16.6.2.3.3. Metabolic Diseases
16.6.2.3.4. Oncology
16.6.2.3.5. Tissue Homeostasis and Repair
16.6.2.3.6. Cardio-vascular diseases
16.6.2.3.7. Other
16.6.2.4. Argentina Anti-Aging LongevityÂ
Market Revenue (US$ Mn) and Forecasts, By End user
16.6.2.4.1. Hospital and Clinics
16.6.2.4.2. Academic and Research Institutions
16.6.2.4.3. Others
16.6.3. Rest of Latin America
16.6.3.1. Rest of Latin America Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Clinical Phases
16.6.3.1.1. Research and Pre-Clinical
16.6.3.1.2. Phase I
16.6.3.1.3. Phase II
16.6.3.1.4. Phase III
16.6.3.2. Rest of Latin America Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By
Therapy
16.6.3.2.1. Senolytic Drug Therapy
16.6.3.2.2. Gene Therapy
16.6.3.2.3. Immunotherapy
16.6.3.2.4. Stem Cell Therapy
16.6.3.2.5. Others
16.6.3.3. Rest of Latin America Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts,
By Indication
16.6.3.3.1. Neurogenerative Diseases
16.6.3.3.2. Ophthalmic Conditions
16.6.3.3.3. Metabolic Diseases
16.6.3.3.4. Oncology
16.6.3.3.5. Tissue Homeostasis and Repair
16.6.3.3.6. Cardio-vascular diseases
16.6.3.3.7. Other
16.6.3.4. Rest of Latin America Anti-Aging Longevity Market Revenue (US$ Mn) and Forecasts, By End
user
16.6.3.4.1. Hospital and Clinics
16.6.3.4.2. Academic and Research Institutions
16.6.3.4.3. Others
16.7. Key
Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Clinical Phases
16.7.3. By Therapy
16.7.4. By Indication
16.7.5. By End user
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market
Share Analysis, 2021
17.3. Global
Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. AgeX
Therapeutics, Inc.
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Calico
Life Sciences LLC
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. CohBar,
Inc.
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Life
Biosciences, Inc.
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Merck
& Co., Inc
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Oisin
Biotechnologies
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Pfizer
Inc.
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. T.A.
Sciences, Inc.
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Unity
Biotechnology
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Other
Market Participants
19. Key Findings
Note: This ToC is tentative and can be changed
according to the research study conducted
during
the course of report completion.
**Exclusive for Multi-User
and Enterprise User.
Â
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.